Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Radiotherapy for Hodgkin Lymphoma: Reducing Toxicity While Maintaining Efficacy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effects of exercise on tumor physiology and metabolism

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

DNA methyltransferase inhibitors, so-called hypomethylating agents (HMAs), are the only drugs approved for the treatment of higher-risk myelodysplastic syndromes and are widely used in this context. However, it is still unclear why some patients respond to HMAs, whereas others do not. Recent sequencing efforts have identified molecular disease entities that may be specifically sensitive to these drugs, and many attempts are being made to clarify how HMAs affect the malignant clone during treatment. Here, we review the most recent data on the clinical effects of HMAs in myeloid malignancies.

OriginalsprogEngelsk
TidsskriftCancer Journal
Vol/bind23
Udgave nummer5
Sider (fra-til)277-285
Antal sider9
ISSN1528-9117
DOI
StatusUdgivet - 1 sep. 2017

ID: 52056014